FDA decision expected by July 30, 2025
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
Seeking Alpha / 1 hour from now 1 Views
FDA decision expected by July 30, 2025
Comments